← Back to Screener
Galecto, Inc. Common Stock (GLTO)
Price$26.60
Favorite Metrics
Price vs S&P 500 (26W)101.36%
Price vs S&P 500 (4W)37.14%
Market Capitalization$1.73B
All Metrics
Book Value / Share (Quarterly)$6.03
P/TBV (Annual)0.26x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-9.21
Price vs S&P 500 (YTD)11.46%
EPS (TTM)$-12.01
10-Day Avg Trading Volume0.29M
EPS Excl Extra (TTM)$-12.01
EPS (Annual)$-18.53
ROI (Annual)-135.42%
Cash / Share (Quarterly)$5.73
ROA (Last FY)-125.14%
EBITD / Share (TTM)$-12.47
ROE (5Y Avg)-83.79%
Cash Flow / Share (Annual)$-14.14
P/B Ratio215.85x
P/B Ratio (Quarterly)0.62x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-145.71x
ROA (TTM)-111.33%
EPS Incl Extra (Annual)$-18.53
Current Ratio (Annual)14.07x
Quick Ratio (Quarterly)3.71x
3-Month Avg Trading Volume0.22M
52-Week Price Return1017.65%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.38
52-Week High$38.33
EPS Excl Extra (Annual)$-18.53
26-Week Price Return110.11%
Quick Ratio (Annual)12.65x
13-Week Price Return6.44%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.73x
Enterprise Value$1,720.682
Revenue / Employee (Annual)$0
Cash / Share (Annual)$10.76
3-Month Return Std Dev123.66%
Net Income / Employee (TTM)$-3
ROE (Last FY)-135.42%
Net Interest Coverage (Annual)-151.27x
EPS Basic Excl Extra (Annual)$-18.53
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-12.01
Receivables Turnover (Annual)0.00x
ROI (TTM)-130.67%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.41
Price vs S&P 500 (52W)982.55%
Year-to-Date Return15.60%
5-Day Price Return0.64%
EPS Normalized (Annual)$-18.53
ROA (5Y Avg)-74.46%
Month-to-Date Return2.70%
Cash Flow / Share (TTM)$-1.74
EBITD / Share (Annual)$-19.22
ROI (5Y Avg)-83.79%
EPS Basic Excl Extra (TTM)$-12.01
P/TBV (Quarterly)0.44x
P/B Ratio (Annual)0.39x
Book Value / Share (Annual)$12.02
Price vs S&P 500 (13W)3.58%
Beta1.56x
Revenue / Share (TTM)$0.00
ROE (TTM)-130.67%
52-Week Low$2.35
Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.29
4.29
4.38
4.30
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GLTOGalecto, Inc. Common Stock | — | — | — | — | $26.60 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors of galectin-3 and LOXL2 for cancer and liver diseases. Its pipeline includes three candidates: GB0139 for idiopathic pulmonary fibrosis, GB1211 for NASH-related fibrosis, and GB2064 for myelofibrosis.